Mirati Therapeutics (DB:26M) - Prezzo delle azioni, notizie e analisi

26M Panoramica delle azioni

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. Maggiori dettagli

26M analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 87.2% al di sotto della nostra stima del suo valore equo

Si prevede che i ricavi cresceranno 42.24% all'anno

Analisi del rischio

Gli azionisti sono stati diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Importanti vendite da parte di insider negli ultimi 3 mesi

Mirati Therapeutics, Inc. Concorrenti

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€857.2m

Heidelberg Pharma

XTRA:HPHA

€105.8m

SCHOTT Pharma KGaA

XTRA:1SXP

€4.1b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Mirati Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$53.30
Massimo di 52 settimane	US$59.46
Minimo di 52 settimane	US$25.13
Beta	0.77
1Variazione di 1 mese	0.95%
Variazione a 3 mesi	2.74%
Variazione di 1 anno	22.25%
3Variazione a 3 anni	-69.72%
Variazione a 5 anni	-1.55%
Variazione dall'IPO	247.67%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	26M	DE Biotechs	DE Mercato
7D	-2.0%	-1.1%	1.1%
1Y	22.2%	-18.8%	7.2%

Ritorno vs Industria: 26M ha superato il German Biotechs che ha restituito -18.8 % nell'ultimo anno.

Rendimento vs Mercato: 26M ha superato il mercato German che ha restituito 7.2 % nell'ultimo anno.

Volatilità dei prezzi

Is 26M's price volatile compared to industry and market?
26M volatility
26M Average Weekly Movement	1.4%
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: 26M non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di 26M è diminuita da 10% a 1% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1995	587	Chuck Baum	www.mirati.com

Mirati Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Mirati Therapeutics con la sua capitalizzazione di mercato?
26M statistiche fondamentali
Capitalizzazione di mercato	€3.79b
Guadagni(TTM)	-€668.10m
Ricavi(TTM)	€35.15m

107.8x

Rapporto P/S

-5.7x

Rapporto P/E

26M è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
26M Conto economico (TTM)
Ricavi	US$38.19m
Costo del fatturato	US$510.48m
Profitto lordo	-US$472.29m
Altre spese	US$253.59m
Guadagni	-US$725.88m

Ultimi guadagni dichiarati

Sep 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-10.35
Margine lordo	-1,236.66%
Margine di profitto netto	-1,900.65%
Rapporto debito/patrimonio netto	0%

Come si è comportato 26M nel lungo periodo?

Vedi performance storica e confronto

26M Panoramica delle azioni

Premi

Analisi del rischio

Mirati Therapeutics, Inc. Concorrenti

XTRA:BIO3

€1.3b

XTRA:FYB

€857.2m

XTRA:HPHA

€105.8m

XTRA:1SXP

€4.1b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings released: US$2.49 loss per share (vs US$3.09 loss in 3Q 2022)

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings released: US$2.49 loss per share (vs US$3.09 loss in 3Q 2022)

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Insufficient new directors

Second quarter 2023 earnings released: US$3.04 loss per share (vs US$3.18 loss in 2Q 2022)

New minor risk - Insider selling

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Chief Financial Officer recently sold €161k worth of stock

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Insufficient new directors

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

CEO & Director recently sold €125k worth of stock

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Founder recently sold €160k worth of stock

Executive VP & Chief Scientific Officer recently sold €98k worth of stock

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Executive VP & Chief Scientific Officer recently sold €148k worth of stock

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Mirati Therapeutics, Inc. Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C -Mutated Gastrointestinal Cancers

Chief Commercial Officer recently sold €67k worth of stock

Chief Commercial Officer recently sold €235k worth of stock

Chief Scientific Officer recently sold €139k worth of stock

High number of new directors

High number of new directors

Independent Director Michael Grey has left the company

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 2000 Growth Index

Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation

Chief Scientific Officer recently sold €55k worth of stock

Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021

Rendimenti per gli azionisti

Volatilità dei prezzi